![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Genentech Inks Licensing Deal With Kiniksa Pharmaceuticals
Genentech Inks Licensing Deal With Kiniksa Pharmaceuticals
Genentech has inked a licensing and development deal with Bermuda-based biotech Kiniksa Pharmaceuticals for the company’s investigational drug vixarelimab.
The monoclonal antibody targets oncostatin M receptor beta. Genentech will focus its efforts on the drug candidate for treatment of fibrosis, given its potential for treating oncostatin M-mediated disease.
Kiniksa intends to complete its ongoing phase 2b clinical trial investigating the drug as a treatment for the skin disease prurigo nodularis.
Kiniksa will receive $100 million in upfront and near-term payments and is also eligible to receive up to approximately $600 million for achieving clinical, regulatory and sales-based milestones.
Upcoming Events
-
21Oct